Biochemistry of cancer

Strategic objectives
Early diagnosis of cancer and its treatment.
Main lines of research
1. Tumor markers: Abnormal Glycosylation of several proteins as potential tumor markers. Currently focused on prostate and pancreatic tumors, particularly in abnormal glycosylation of human pancreatic ribonuclease, acute phase proteins and PSA (prostate specific antigen). Extensible to other glycoproteins.
2. Molecular mechanisms responsible for changes in glycosylation in tumors:
· Expression studies of glycosyltransferases responsible for the biosynthesis of antigens associated to tumors
· Determination of their involvement in various stages of tumor progression and the factors that regulate their expression
3. Mechanisms of tumoral resistance.
· Molecular and cellular mechanisms determining the resistance of tumors to current therapies.
· Studies of the mechanisms of resistance to new agents for the emergence of ligand autocrine loop via the EGF / ErbB.
4. New anti-tumor agents.
· EGF analogues as anti-tumor agents. Antitumor effects of EGF truncated derivatives.
· Obtaining new derivatives as cytotoxic vehicles.
· Studies combined with other therapeutic agents such as those derived from metals: cisplatin, ruthenium and copper.
Early diagnosis of cancer and its treatment.
Group Leaders
Rafael de Llorens and Rosa Peracaula
Senior researchers
Rosa Nuria Aleixandre
Silvia Barrabés
Josep Comet
Mª José Ferri
Esther Llop
Mª Ángeles Martínez
Anna Massaguer
Medical researcher:
Manel Ramírez
Post-graduate researchers
Mertixell Balmaña
Montserrat Ferrer
Eva Plà



Are you investigator?


If you research if you are interested in helping with any of our research groups, fill out this form. We will contact you as soon as possible. Thank you.

Send us your details

Read More